This expert panel of Australian medical oncologists present three much-anticipated metastatic breast cancer studies presented at the European Society of Medical Oncology (ESMO) 2021. The Destiny Breast 03 trial, the KEYNOTE-355 study and the MONALEESA-2 trial.
- In this video, our Australian thought-leaders present and analyse the first-ever comparative trial of two different antibodies drugs in HER2 positive metastatic breast cancer in the Destiny Breast 03 trial.
- The expert panellists continue to discuss the KEYNOTE-355 study, which examines the effect of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy in metastatic triple-negative breast cancer.
- Finally, the panel discuss the analysis of the overall survival results of the phase-III MONALEESA-2 trial of post-menopausal patients with HR=/HER2- advanced breast cancer treated with endocrine therapy +/- ribociclib.
This program is supported by an independent and unrestricted educational grant by Astra Zeneca.